- Chengdu microbial manufacturing site spans ~95,000 m² and targets GMP release for commercial production by end‑2026.
- Facility includes a 15,000 L fermenter (up to 110 DS batches/year) with expansion potential to 60,000 L and a multi‑tier scale‑up platform (15 L, 3,000 L, 15,000 L).
- Features China’s first dual‑chamber lyophilization line co‑developed with VISEN Pharmaceuticals and a vial‑filling line with >10 million DP vials/year capacity.
- Powered by the EffiX E. coli expression system achieving recombinant protein titers up to 15 g/L, the microbial platform had supported development/manufacturing of 128 molecules by end‑2025.
Project overview
Structural completion and key equipment arrival mark progress at the Chengdu microbial commercial manufacturing site in Wenjiang District, which broke ground last June and spans approximately 95,000 m²; the site is targeting GMP release for commercial production by the end of 2026.
Manufacturing capacity
The facility houses a 15,000 L fermenter enabling up to 110 drug‑substance batches per year with long‑term expansion potential to 60,000 L, a vial‑filling line capable of producing over 10 million drug‑product vials annually, and China’s first dual‑chamber lyophilization line developed with VISEN Pharmaceuticals.
Technology platform
The microbial platform uses the EffiX E. coli expression system with reported recombinant protein titers up to 15 g/L, supports multi‑tier scale‑up (15 L, 3,000 L, 15,000 L), and offers a CMC package workflow from plasmid DNA to IND filing within six months; by the end of 2025 the platform had supported development and manufacturing of 128 molecules.
Operations and sustainability
Integrated automation and digital systems are implemented across upstream and downstream operations to support reliable GMP manufacturing, compliance and data integrity, while green building measures—such as sponge city design and photovoltaic modules—are incorporated to enhance resource and energy efficiency.
